Skip to content

Accelerating Biosimilar Adoption: Conversation with the Experts

Multiple Sclerosis Biosimilars Landscape

Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab being developed to treat relapsing forms of MS including clinicallyContinue reading “Multiple Sclerosis Biosimilars Landscape”

The Global Use of Medicines 2023

Biosimilar Product Information

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations

Biosimilars – Providing Affordable, Accessible Care for Patients

BIosimilar Report 2023 (Cardinal)

Biosimilars (FDA resource)

Formulary Monograph Services